Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02866409
Other study ID # NK/1062/MD/13422-423
Secondary ID
Status Completed
Phase Phase 2
First received August 3, 2016
Last updated August 10, 2016
Start date November 2013
Est. completion date January 2015

Study information

Verified date August 2016
Source Postgraduate Institute of Medical Education and Research
Contact n/a
Is FDA regulated No
Health authority India: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study has been designed to assess the efficacy of dexmedetomidine as an adjuvant to local anaesthetic agent bupivacaine in scalp nerve block and scalp infiltration to control post craniotomy pain.A third group where patients were administered bupivacaine only infiltration has also been created.


Description:

Patients were randomly allocated into three equal groups by computer generated random numbers. For randomization, the simple random allocation rule was followed, wherein the total sample size (n = 150) was randomly divided into three equal groups. In the event of any case has to be excluded because of requirement of postoperative ventilation, altered sensorium or high grade fever in the post-operative period, the same random number code was allocated to the next patient in order to ensure an equal sample size without any modification to the original random number table. The random numbers were then kept in opaque sealed envelopes, numbered sequentially which were opened just before shifting patient inside operation theatre.

The anaesthesiologist who prepared and administered the study drug were not involved in collection of data. The anaesthesiologist who collected the data from the patient in the postoperative period, the operating surgeon and the patient were blinded to the group assigned to the patient.

Pre-operative Assessment:

Pre-operative anaesthetic evaluation was done on the day prior to the surgery. This included a detailed history regarding physical health, any co-morbid illness, current medications, drug allergy and previous anaesthetic experience. The patient was made familiar about the NRS (0-10, with 0 = no pain, 10 = worst pain ever). A written and informed consent was taken. Patients were fasted and premedicated according to the departmental protocol.

Duration of study period-

Study period started after closure of skin incision of the scalp and continued till 48 hours in the postoperative period

Study groups-

Patients were randomly divided into three groups:

Group BI - Bupivacaine infiltration around surgical incision.

Group BDI - Bupivacaine and dexmedetomidine infiltration around surgical incision

Group BDNB- Bupivacaine and dexmedetomidine used in scalp nerve block.

Anaesthesia Technique-

A standard anaesthesia technique according to the departmental protocol was followed in all the patients. Pre-induction monitoring (Datex- Ohmeda S/5 Avance, Madison, WI, USA) consisted of 5-lead electrocardiography, heart rate, automated non-invasive blood pressure, and pulse oximetry. The patients were then be induced with propofol (1-2 mg/kg) or thiopentone (4-6mg/kg) and trachea were intubated with vecuronium 0.1 mg/kg. Anaesthesia was maintained with intravenous (propofol) or inhalational (isoflurane/sevoflurane/desflurane) anaesthetic agent along with nitrous oxide-oxygen mixture (60:40) and intermittent doses of intravenous vecuronium (0.02 mg/kg). Ventilation was maintained at ETCO2 30 to 35mm Hg. Total fresh gas flow rate was kept at 1-2 L/min. A radial artery catheter was inserted for continuous blood pressure monitoring and blood sampling if indicated. Intraoperative analgesia was maintained with intravenous morphine 0.1mg/kg and morphine repeated at a dose of 0.05 mg/kg if duration of surgery was more than 3 hours. Patients were reversed with neostigmine (0.05mg/kg) and glycopyrolate (0.01mg/kg) after administration of study drugs and were extubated once patient started responding to verbal commands and able to generate adequate tidal volume under spontaneous respiration.

Methods of postoperative analgesia- In all the patients, analgesic procedure was done ensuring proper aseptic precaution at the end of the surgery, after closure of skin incision and before putting the dressings over the incision. Patients were reversed from anaesthesia after the administration of study drugs.

Group BI: The incision site was infiltrated with 15-20 ml of bupivacaine (0.25%). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.

Group BDI: The incision site was infiltrated with 15-20 ml bupivacaine (0.25%) and dexmedetomedine (1 µg/kg). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.

Group BDNB: Scalp nerve blocks were given with15-20 ml of combination of Bupivacaine (0.25%) and Dexmedetomedine (1 µg/kg). Maximum dose of bupivacaine kept less than 2 mg /kg.

In this group following nerves were blocked-

1. Supra-orbital nerve

2. Supra-trochlear nerve

3. Zygomatico-temporal nerve

4. Auriculo-temporal nerve

5. Posterior auricular branches of the greater auricular Nerve

6. The greater, lesser, and third occipital nerves

Post-operative assessment:

After extubation patients were shifted to the Post anaesthesia care unit (PACU) and assessed for haemodynamic parameters, sedation and any complication at 15 minutes interval till 2hrs and then at 4, 8, 12, 16, 20, 24, 36 and 48 hours. Assessed for cognitive function at 30 min and 60 min.

Patients were followed after discharge for 6 months by telephonic communication at 1, and 3 month interval for presence of chronic pain.

COLLECTION OF DATA-

Preoperative- Age, sex, weight, ASA status, diagnosis, surgery

Intraoperative-

1. Site of incision

2. Duration of surgery

3. Intra-operative analgesia- morphine in mg/kg

Postoperative-

1. Haemodynamic parameters- Heart rate, systolic and diastolic blood pressure, oxygen saturation was recorded at arrival to PACU and every 15 min interval for 2 hours. Then heart rate and systolic and diastolic blood pressure at 4, 8, 12, 16, 20, 24, 36 and 48 hours after surgery.

2. Respiration rate-was recorded at arrival to PACU and every 15 min interval for 2 hours and then at 4, 8, 12, 16, 20, 24, 36 and 48 hours after surgery.

3. Cognitive function- Patients were evaluated for cognitive function 30 minutes after shifting to PACU using a modified self-devised questionnaire of short orientation memory concentration test.

Whenever the subjects were able to recall and count with minimal mistakes (1 to 3), were regarded as good, with more than 3 mistakes as fair, and if not be able to recall at all, it was regarded as poor. If the cognitive function outcome was poor then same test was repeated at 1 hour after shifting to PACU. If outcome was again poor, then that patient was excluded from the study.

4. Assessment of pain- Postoperative pain was assessed by Numerical rating scale (NRS) where in 0 shows 'no pain' and 10 shows 'worst imaginable excruciating pain'. It was assessed at arrival to PACU and at 0, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 20, 24, 36 and 48 hours after surgery.

5. Pain free period- Time of first rescue analgesic administration from the time of test drug administration was recorded.

6. Postoperatively rescue analgesic- When NRS score was ≥ 4, rescue analgesic paracetamol 1gm was administered intravenously and total rescue analgesic requirement in 24 and 48 hrs were noted.

7. Rescue drugs to maintain haemodynamic stability- Any adverse events like bradycardia (Heart rate ≤ 40), hypotension (SBP < 90 mm of Hg) were recorded and treated by rescue drugs: atropine-15µg/Kg and mephenteramine-3mg/dose respectively. Total amount of rescue drug requirement in 24 and 48 hours were noted.

8. Postoperative sedation- Level of sedation was assessed using Modified Ramsay Sedation Scale.

9. Adverse events-

1. Respiratory depressions (Respiration rate < 8 breaths/min) was recorded and managed accordingly.

2. Postoperative nausea and vomiting (PONV) was assessed on a 4-point scale. and was treated with ondansetron 0.15 mg/kg intravenously if score was >2.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date January 2015
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Neurosurgical patients

- 18-70 years of age

- ASA class I and II

- Patients undergoing elective craniotomy, who were conscious and oriented to time, person and place and able to understand and use Numerical Rating Scale (NRS)

Exclusion Criteria:

- Patient dull and irritable

- GCS <15

- Craniotomy incision extending beyond scalp (the field of the block) e.g. craniofacial surgery

- Patients treated chronically with analgesics or narcotic medications

- Allergy to local anaesthetics or dexmedetomedine

- Patients planned for post-operative mechanical ventilation

Following patients were excluded from the study during collection of data in the postoperative period:-

- Patients developing fever (=39°C) in the postoperative period

- Requiring postoperative ventilation (unplanned)

- Having poor cognitive function at 1 hour postoperative period

- GCS <15 in post-operative period.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Procedure:
scalp block
In this group following nerves were blocked- Supra-orbital nerve Supra-trochlear nerve Zygomatico-temporal nerve Auriculo-temporal nerve Posterior auricular branches of the greater auricular Nerve The greater, lesser, and third occipital nerves
infiltration
The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
Drug:
Dexmedetomidine
Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
Bupivacaine
20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
NAVNEH SAMAGH Postgraduate Institute of Medical Education and Research, Chandigarh

Outcome

Type Measure Description Time frame Safety issue
Other heart rate in beats per minute(bpm) 15 minutes interval till 2hrs post extubation 15 minutes interval till 2hrs No
Other heart rate in beats per minute(bpm) 4 hours. No
Other heart rate in beats per minute(bpm) 8 hours. No
Other heart rate in beats per minute(bpm) 12 hours. No
Other heart rate in beats per minute(bpm) 16 hours. No
Other heart rate in beats per minute(bpm) 20 hours. No
Other heart rate in beats per minute(bpm) 24 hours. No
Other heart rate in beats per minute(bpm) 36 hours. No
Other heart rate in beats per minute(bpm) 48 hours. No
Other systolic blood pressure in mm of Hg 15 minutes interval till 2hrs post extubation 15 minutes interval till 2hrs No
Other systolic blood pressure in mm of Hg 4 hours. No
Other systolic blood pressure in mm of Hg 8 hours. No
Other systolic blood pressure in mm of Hg 12 hours. No
Other systolic blood pressure in mm of Hg 16 hours. No
Other systolic blood pressure in mm of Hg 20 hours. No
Other systolic blood pressure in mm of Hg 24 hours. No
Other systolic blood pressure in mm of Hg 36 hours. No
Other systolic blood pressure in mm of Hg 48 hours. No
Other Diastolic blood pressure in mm of Hg 15 minutes interval till 2hrs post extubation 15 minutes interval till 2hrs No
Other Diastolic blood pressure in mm of Hg 4 hours. No
Other Diastolic blood pressure in mm of Hg 8 hours. No
Other Diastolic blood pressure in mm of Hg 12 hours. No
Other Diastolic blood pressure in mm of Hg 16 hours. No
Other Diastolic blood pressure in mm of Hg 20 hours. No
Other Diastolic blood pressure in mm of Hg 24 hours. No
Other Diastolic blood pressure in mm of Hg 36 hours. No
Other Diastolic blood pressure in mm of Hg 48 hours. No
Other SpO2 in percentage 15 minutes interval till 2hours. No
Other SpO2 in percentage 4 hours. No
Other SpO2 in percentage 8 hours. No
Other SpO2 in percentage 12 hours. No
Other SpO2 in percentage 16 hours. No
Other SpO2 in percentage 20 hours. No
Other SpO2 in percentage 24 hours. No
Other SpO2 in percentage 36 hours. No
Other SpO2 in percentage 48 hours. No
Other respiratory rate in breaths per minute respiratory rate in breaths per minute at 15 minutes interval till 2hrs in post operative period after extubation 15 minutes interval till 2hrs No
Other respiratory rate in breaths per minute 4 hours. No
Other Respiratory rate in breaths per minute 8 hours. No
Other Respiratory rate in breaths per minute 12 hours. No
Other Respiratory rate in breaths per minute 16 hours. No
Other Respiratory rate in breaths per minute 20 hours. No
Other Respiratory rate in breaths per minute 24 hours. No
Other Respiratory rate in breaths per minute 36 hours. No
Other Respiratory rate in breaths per minute 48 hours. No
Other cognitive function using Modified self-devised questionnaire of short orientation memory concentration Modified self-devised questionnaire of short orientation memory concentration test
What date is it today?
What is the current year?
What is his/her birthday?
Count numbers 1 to 10.
Count reverse numbers from 10 to 1.
30 minutes No
Other cognitive function using Modified self-devised questionnaire of short orientation memory concentration Modified self-devised questionnaire of short orientation memory concentration test
What date is it today?
What is the current year?
What is his/her birthday?
Count numbers 1 to 10.
Count reverse numbers from 10 to 1.
60 minutes No
Other post operative nausea vomiting using Postoperative Nausea and Vomiting Scale Postoperative Nausea and Vomiting Scale
No PONV: Absence of any emesis or nausea.
Mild PONV: Patient having only mild nausea / one emetic episode / nausea lasting for less than 10 minutes and where no antiemetic is required.
Moderate PONV: Patient has 1-2 emetic episodes / moderate to severe nausea and antiemetic therapy is required.
Severe PONV: Patient has more than 2 emetic episodes / is nauseated more than twice & more than one antiemetic required.
15 minutes interval till 2hrs No
Other post operative nausea vomiting using Postoperative Nausea and Vomiting Scale Postoperative Nausea and Vomiting Scale
No PONV: Absence of any emesis or nausea.
Mild PONV: Patient having only mild nausea / one emetic episode / nausea lasting for less than 10 minutes and where no antiemetic is required.
Moderate PONV: Patient has 1-2 emetic episodes / moderate to severe nausea and antiemetic therapy is required.
Severe PONV: Patient has more than 2 emetic episodes / is nauseated more than twice & more than one antiemetic required.
4 hours. No
Other post operative nausea vomiting using Postoperative Nausea and Vomiting Scale Postoperative Nausea and Vomiting Scale
No PONV: Absence of any emesis or nausea.
Mild PONV: Patient having only mild nausea / one emetic episode / nausea lasting for less than 10 minutes and where no antiemetic is required.
Moderate PONV: Patient has 1-2 emetic episodes / moderate to severe nausea and antiemetic therapy is required.
Severe PONV: Patient has more than 2 emetic episodes / is nauseated more than twice & more than one antiemetic required.
8 hours. No
Other post operative nausea vomiting using Postoperative Nausea and Vomiting Scale Postoperative Nausea and Vomiting Scale
No PONV: Absence of any emesis or nausea.
Mild PONV: Patient having only mild nausea / one emetic episode / nausea lasting for less than 10 minutes and where no antiemetic is required.
Moderate PONV: Patient has 1-2 emetic episodes / moderate to severe nausea and antiemetic therapy is required.
Severe PONV: Patient has more than 2 emetic episodes / is nauseated more than twice & more than one antiemetic required.
12 hours. No
Other post operative nausea vomiting using Postoperative Nausea and Vomiting Scale Postoperative Nausea and Vomiting Scale
No PONV: Absence of any emesis or nausea.
Mild PONV: Patient having only mild nausea / one emetic episode / nausea lasting for less than 10 minutes and where no antiemetic is required.
Moderate PONV: Patient has 1-2 emetic episodes / moderate to severe nausea and antiemetic therapy is required.
Severe PONV: Patient has more than 2 emetic episodes / is nauseated more than twice & more than one antiemetic required.
16 hours. No
Other post operative nausea vomiting using Postoperative Nausea and Vomiting Scale Postoperative Nausea and Vomiting Scale
No PONV: Absence of any emesis or nausea.
Mild PONV: Patient having only mild nausea / one emetic episode / nausea lasting for less than 10 minutes and where no antiemetic is required.
Moderate PONV: Patient has 1-2 emetic episodes / moderate to severe nausea and antiemetic therapy is required.
Severe PONV: Patient has more than 2 emetic episodes / is nauseated more than twice & more than one antiemetic required.
20 hours. No
Other post operative nausea vomiting using Postoperative Nausea and Vomiting Scale Postoperative Nausea and Vomiting Scale
No PONV: Absence of any emesis or nausea.
Mild PONV: Patient having only mild nausea / one emetic episode / nausea lasting for less than 10 minutes and where no antiemetic is required.
Moderate PONV: Patient has 1-2 emetic episodes / moderate to severe nausea and antiemetic therapy is required.
Severe PONV: Patient has more than 2 emetic episodes / is nauseated more than twice & more than one antiemetic required.
24 hours. No
Other post operative nausea vomiting using Postoperative Nausea and Vomiting Scale Postoperative Nausea and Vomiting Scale
No PONV: Absence of any emesis or nausea.
Mild PONV: Patient having only mild nausea / one emetic episode / nausea lasting for less than 10 minutes and where no antiemetic is required.
Moderate PONV: Patient has 1-2 emetic episodes / moderate to severe nausea and antiemetic therapy is required.
Severe PONV: Patient has more than 2 emetic episodes / is nauseated more than twice & more than one antiemetic required.
36 hours. No
Other post operative nausea vomiting using Postoperative Nausea and Vomiting Scale Postoperative Nausea and Vomiting Scale
No PONV: Absence of any emesis or nausea.
Mild PONV: Patient having only mild nausea / one emetic episode / nausea lasting for less than 10 minutes and where no antiemetic is required.
Moderate PONV: Patient has 1-2 emetic episodes / moderate to severe nausea and antiemetic therapy is required.
Severe PONV: Patient has more than 2 emetic episodes / is nauseated more than twice & more than one antiemetic required.
48 hours. No
Primary post craniotomy pain by Numerical rating scale (NRS) Numerical rating scale (NRS) is a scale from 0 to 10 where 0 shows 'no pain' and 10 shows 'worst imaginable excruciating pain Immediately after extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 30 minutes after extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 1 hour after extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 1.5 hours after extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 2 hours after extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 4 hours post extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 8 hours post extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 12 hours post extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 16 hours post extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 20 hours post extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 24 hours post extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 36 hours post extubation No
Primary post craniotomy pain by Numerical rating scale (NRS) 48 hours post extubation No
Secondary chronic pain using Numerical rating scale (NRS) Numerical rating scale (NRS) is a scale from 0 to 10 where 0 shows 'no pain' and 10 shows 'worst imaginable excruciating pain 1 month No
Secondary chronic pain using Numerical rating scale (NRS) 3 months No
Secondary post operative sedation using Modified Ramsay Sedation Scale Sedation Score-- by Modified Ramsay Sedation Scale
Anxious/ Agitated/ Restless
Cooperative/ Oriented/ Tranquil
Responds to verbal commands
Brisk response to light glabellar tap or loud noise
Sluggish response to light glabellar tap or loud noise
No Response
15 minutes interval till 2hrs post extubation and then at 4, 8, 12, 16, 20, 24, 36 and 48 hours. No
Secondary post operative sedation using Modified Ramsay Sedation Scale Sedation Score-- by Modified Ramsay Sedation Scale
Anxious/ Agitated/ Restless
Cooperative/ Oriented/ Tranquil
Responds to verbal commands
Brisk response to light glabellar tap or loud noise
Sluggish response to light glabellar tap or loud noise
No Response
4 hours No
Secondary post operative sedation using Modified Ramsay Sedation Scale Sedation Score-- by Modified Ramsay Sedation Scale
Anxious/ Agitated/ Restless
Cooperative/ Oriented/ Tranquil
Responds to verbal commands
Brisk response to light glabellar tap or loud noise
Sluggish response to light glabellar tap or loud noise
No Response
8 hours. No
Secondary post operative sedation using Modified Ramsay Sedation Scale Sedation Score-- by Modified Ramsay Sedation Scale
Anxious/ Agitated/ Restless
Cooperative/ Oriented/ Tranquil
Responds to verbal commands
Brisk response to light glabellar tap or loud noise
Sluggish response to light glabellar tap or loud noise
No Response
12 hours. No
Secondary post operative sedation using Modified Ramsay Sedation Scale Sedation Score-- by Modified Ramsay Sedation Scale
Anxious/ Agitated/ Restless
Cooperative/ Oriented/ Tranquil
Responds to verbal commands
Brisk response to light glabellar tap or loud noise
Sluggish response to light glabellar tap or loud noise
No Response
16 hours. No
Secondary post operative sedation using Modified Ramsay Sedation Scale Sedation Score-- by Modified Ramsay Sedation Scale
Anxious/ Agitated/ Restless
Cooperative/ Oriented/ Tranquil
Responds to verbal commands
Brisk response to light glabellar tap or loud noise
Sluggish response to light glabellar tap or loud noise
No Response
20 hours. No
Secondary post operative sedation using Modified Ramsay Sedation Scale Sedation Score-- by Modified Ramsay Sedation Scale
Anxious/ Agitated/ Restless
Cooperative/ Oriented/ Tranquil
Responds to verbal commands
Brisk response to light glabellar tap or loud noise
Sluggish response to light glabellar tap or loud noise
No Response
24 hours. No
Secondary post operative sedation using Modified Ramsay Sedation Scale Sedation Score-- by Modified Ramsay Sedation Scale
Anxious/ Agitated/ Restless
Cooperative/ Oriented/ Tranquil
Responds to verbal commands
Brisk response to light glabellar tap or loud noise
Sluggish response to light glabellar tap or loud noise
No Response
36 hours. No
Secondary post operative sedation using Modified Ramsay Sedation Scale Sedation Score-- by Modified Ramsay Sedation Scale
Anxious/ Agitated/ Restless
Cooperative/ Oriented/ Tranquil
Responds to verbal commands
Brisk response to light glabellar tap or loud noise
Sluggish response to light glabellar tap or loud noise
No Response
48 hours. No
Secondary rescue analgesic requirement in grams total rescue analgesic requirement in grams of paracetamol consumed in 24 hours 24 hrs No
Secondary rescue analgesic requirement in grams total rescue analgesic requirement in grams of paracetamol consumed in 48 hours 48 hrs No
See also
  Status Clinical Trial Phase
Withdrawn NCT03472872 - A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache Phase 4
Withdrawn NCT05410366 - Safe Harbors in Emergency Medicine, Specific Aim 3
Withdrawn NCT02866084 - Neuromodulation Treatment of Vestibular Migraines N/A
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Not yet recruiting NCT04352218 - Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache Phase 2
Completed NCT02734992 - Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers N/A
Completed NCT01327118 - Prostaglandin F2alpha in a Human Headache Model N/A
Completed NCT01153789 - Study of Oculomotor Dysfunction Leading to Children Vertigo N/A
Not yet recruiting NCT00969995 - Identification of Inflammatory Markers in Migraine Patients N/A
Not yet recruiting NCT00752921 - Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache Phase 4
Terminated NCT00291395 - PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers Phase 1
Completed NCT00212810 - Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Phase 4
Completed NCT00263094 - An End to the Yom Kippur (and Ramadan) Headache N/A
Completed NCT00135122 - Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache Phase 3
Completed NCT02475005 - An Intervention to Improve Adolescent Headache Self-management N/A
Completed NCT03163901 - The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury N/A
Completed NCT01664585 - Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life N/A
Completed NCT04632420 - Evaluation of Headache and Childbirth in a Chronic Pain Population
Recruiting NCT05033613 - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease